drugset / Trial / NCT01712009
NOLAN: Naproxen or Loratadine and Neulasta
RandomizedParallel-groupOpen-labelTreatment
Summary
The primary objective of the study is to estimate the difference in bone pain between breast cancer patients receiving chemotherapy and pegfilgrastim and either no prophylactic intervention, prophylactic naproxen, or prophylactic loratadine.
Timeline
- Start
- 2012-11-01
- Primary completion
- 2015-03-18
- Completion
- 2015-03-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Loratadine | Small molecule | 10 mg | — |
| Subject | Naproxen | Small molecule | 500 mg | Oral |
| Background | Pegfilgrastim | Protein / enzyme biologic | 6 mg | Subcutaneous |